ProfoundBio (Suzhou) Co., Ltd.

It has been a tough month for Genmab, with Johnson & Johnson opting out of a pact and a lawsuit landing from AbbVie, but the Danish biotech has come out fighting with the announcement of a new sha

The pressure on Genmab to deliver positive results from its late-stage development programs has intensified now that the most closely watched event on the company’s 2025 calendar has arrived and the r

Developing antibody therapeutics, out-licensing the drugs to larger companies and collecting royalty revenue from the resulting commercial products has been a lucrative business for Genmab. However, f

Developing antibody therapeutics, out-licensing the drugs to larger companies and collecting royalty revenue from the resulting commercial products has been a lucrative business for Genmab. However, f